2025 年第 1 期 第 20 卷

利肺胶囊联合茶碱缓释片治疗慢性喘息性支气管炎的临床效果研究

Clinical effect of Lifei capsules combined with theophylline sustained-release tablets in the treatment of chronic asthmatic bronchitis

作者：冯志超1 王存林1 张彤1 任筱璐2

英文作者：Feng Zhichao1 Wang Cunlin1 Zhang Tong1 Ren Xiaolu2

单位：1山西医科大学药学院，太原030604；2山西省肿瘤医院呼吸科，太原030013

英文单位：1College of Pharmacy Shanxi Medical University Taiyuan 030604 China; 2Department of Respiratory Medicine Shanxi Cancer Hospital Taiyuan 030013 China

关键词：慢性喘息性支气管炎；  急性发作；  利肺胶囊；  茶碱缓释片

英文关键词：Chronicasthmaticbronchitis;  Acuteonset;  Lifeicapsules;  Theophyllinesustained-releasetablets

• 摘要：

• 目的  探讨利肺胶囊联合茶碱缓释片治疗慢性喘息性支气管炎的临床效果。方法  选取2022年3月至2023年12月山西省肿瘤医院收治的90例慢性喘息性支气管炎患者为研究对象。按照随机数字表法将90例患者分为对照组和观察组，各45例。对照组在基础治疗基础上加用茶碱缓释片进行治疗，观察组在基础治疗基础上采用利肺胶囊联合茶碱缓释片进行治疗。比较2组的总有效率、临床症状改善时间、血气指标、炎症因子和药物不良反应发生率。结果  观察组总有效率高于对照组［93.3%（42/45）比77.8%（35/45）］，差异有统计学意义（P=0.036）。观察组喘息、咳嗽、痰多的改善时间短于对照组，差异均有统计学意义（均P<0.05）。治疗后2组动脉血氧分压水平均高于治疗前且观察组高于对照组，动脉血二氧化碳分压、C反应蛋白、白细胞介素6及降钙素原水平均低于治疗前且观察组均低于对照组，差异均有统计学意义（均P<0.05）。2组药物不良反应发生率比较差异无统计学意义（P=0.609）。结论  利肺胶囊联合茶碱缓释片治疗慢性喘息性支气管炎可获得较好的临床效果，能有效改善患者的血气指标和体内炎症反应，且安全性较好。

• Objective  To investigate the clinical effect of Lifei capsules combined with theophylline sustained-release tablets in the treatment of chronic asthmatic bronchitis. Methods   A total of 90 patients with chronic asthmatic bronchitis admitted to Shanxi Cancer Hospital from March 2022 to December 2023 were selected as the research objects. According to the random number table method, 90 patients were divided into the control group and the observation group, 45 cases in each group. The control group was treated with theophylline sustained-release tablets on the basis of basic treatment, and the observation group was treated with Lifei capsules combined with theophylline sustained-release tablets on the basis of basic treatment. The total effective rate, improvement time of clinical symptoms, blood gas indexes, inflammatory factors and incidence of adverse drug reactions were compared between the two groups. Results   The total effective rate of the observation group was higher than that of the control group ［93.3%(42/45) vs 77.8%(35/45)］(P=0.036). The improvement times of wheezing, cough and phlegm in the observation group were shorter than those in the control group (all P<0.05). After treatment, the levels of arterial partial pressure of oxygen in the two groups were higher than those before treatment, and that in the observation group was higher than that in the control group. The levels of arterial partial pressure of carbon dioxide, C-reactive protein, interleukin-6 and procalcitonin were lower than those before treatment, and those in the observation group were lower than those in the control group (all P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P=0.609). Conclusion   Lifei capsules combined with theophylline sustained-release tablets can achieve good clinical effect in the treatment of chronic asthmatic bronchitis, which can effectively improve the blood gas indexes and inflammatory response in the body, and has good safety.